Vascular endothelial growth factor pathway by Maitland, Michael L. et al.
Vascular endothelial growth factor pathway
Michael L. Maitlanda, Xing Jian Louc, Jacqueline Ramireza, Apurva A. Desaia, Dorit S.
Berlinc, Howard L. McLeodb, Ralph R. Weichselbauma, Mark J. Rataina, Russ B. Altmanc,
and Teri E. Kleinc
aDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Maryland
Avenue, Chicago, Illinois
bUNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina,
Chapel Hill, Kerr Hall, Chapel Hill, North Carolina
cDepartment of Genetics, Stanford University, Pasteur Drive, Stanford, California, USA
Keywords
angiogenesis; bevacizumab; genetic variation; pharmacogenetics; pharmacogenomics;
PharmGKB; polymorphism; single nucleotide; vascular endothelial growth factor
Description
Agents inhibiting tumor angiogenesis have been developed as a new class of anticancer
agents (reviewed in Ref. [1]). Several of these therapeutics target the vascular endothelial
growth factor (VEGF) signaling pathway (reviewed in Ref. [2]). VEGF comprises several
isoforms which bind to different receptors, including FLT1, KDR, and NRP1, and promote
angiogenesis through activation of a kinase cascade that includes RAS and MAPK. Drugs
that are known to interfere with the normal VEGF signaling pathway include bevacizumab,
a monoclonal antibody; sorafenib and sunitinib, small molecule kinase inhibitors; and
experimental drugs aflibercept, brivanib, cilengitide, axitinib, motesanib, and vandetanib
(Fig. 1).
Bevacizumab, a monoclonal antibody targeting VEGFA, is indicated in combination with
intravenous 5-fluoruracil-based chemotherapy for first-line or second-line treatment of
patients with metastatic carcinoma of the colon or rectum, and in combination with
carboplatin and paclitaxel for first-line treatment of patients with unresectable, locally
advanced, recurrent, or metastatic nonsquamous, nonsmall cell lung cancer. Bevacizumab is
also indicated in combination with paclitaxel for treatment of patients who have not received
chemotherapy for metastatic HER2-negative breast cancer and for glioblastoma, as a single
agent for patients with progressive disease following prior therapy [Avastin (bevacizumab)
drug label: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdf;
retrieved 27 July 2009].
Sorafenib and sunitinib are small molecule kinase inhibitors [3–5]. They have overlapping
activity but differing potency for inhibition of VEGFR1 (FLT1) and VEGFR2 (KDR), and
sorafenib has high potency inhibition of Raf-1 (RAF1) and p38 MAP kinase (MAPK).
Sunitinib has higher potency inhibition for kinases not depicted here. Sorafenib is indicated
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for the treatment of unresectable hepatocellular carcinoma and advanced renal cell
carcinoma [Nexavar (sorafenib) drug label:
http://www.fda.gov/cder/foi/label/2007/021923s004s005s006s007lbl.pdf; retrieved 7 May
2009]. Sunitinib is indicated for the treatment of gastrointestinal stromal tumor after disease
progression or intolerance to imatinib mesylate and for advanced renal cell carcinoma
[Sutent (sunitinib) drug label:
http://www.fda.gov/cder/foi/label/2007/021968s002s003s004s005s006lbl.pdf; retrieved
May 7, 2009]. Brivanib, cilengitide, axitinib, motesanib, and vandetanib are experimental
drugs influencing the angiogenesis pathway as depicted in Fig. 1 [6–11].
Recently, an association was found between VEGFA genotype and treatment outcome in a
trial of paclitaxel compared with paclitaxel plus bevacizumab to treat metastatic breast
cancer [12]. The AA genotype of VEGF: − 2578C > A (rs699947), a promoter
polymorphism, was associated with superior median overall survival in patients receiving
both paclitaxel and bevacizumab. Patients in the combination arm who carried the A allele
of VEGF: − 1154G > A (rs1570360) also showed superior median overall survival. These
results will require confirmation to support a role for VEGFA polymorphisms in affecting
clinical outcome following bevacizumab treatment for metastatic breast cancer.
Several studies have investigated variants in angiogenesis pathway genes for association
with disease risk. Studies focusing on VEGFA have produced conflicting results: Schneider
et al. [13] reported that the A allele of VEGFA: − 2578C > A (rs1547651) and the C allele
of VEGFA: − 1498T > C (rs833061) are associated with increased breast cancer risk. Lu et
al. [14] found that the − 460C (rs833061) and +405G (rs2010963) VEGFA alleles were
significantly associated with reduced overall survival after diagnosis of breast cancer, and
that the − 460T/+405C/+936C (rs3025039) haplotype was significantly associated with
increased overall survival. A large-scale evaluation of single nucleotide polymorphisms
(SNPs) identified four SNPs in the VEGFA promoter region [the TT genotype of
VEGFA:Ex1-73C > T (rs25648) the AA genotype of VEGFA: − 15648A > C (rs833052),
the TT genotype of VEGFA: − 9228G > T (rs1109324), and the TT genotype of VEGFA: −
8339A > T (rs1547651)] that were associated with increased bladder cancer risk and one
intronic SNP associated with reduced bladder cancer risk [the CT genotype of
VEGFA:IVS2+1378C > T (rs3024994)] [15]. The CC genotype of VEGFA: − 1498T > C
(rs833061) has been shown to be associated with decreased risk of bone metastases in breast
cancer patients [16]. Other research has shown no association between VEGFA variants and
risk of developing breast cancer [17–19], colorectal cancer [20], prostate cancer [21], or
non-small cell lung cancer [22].
Selected polymorphisms in other VEGF pathway genes, including KDR, FLT1, NOS3, and
NRP1 were not associated with breast cancer risk [13]. The same study also found that the
NOS3: − 786TT (rs2070744) genotype is significantly associated with greater likelihood of
invasive breast cancer, and that the NOS3: 894GG (rs1799983) genotype is associated with
increased likelihood of having metastatic disease. Further research is necessary to clarify the
role of angiogenesis pathway gene variants in disease etiology and drug treatment outcome.
As a guide to future investigation of potential mechanisms of inter-individual variability of
efficacy and toxicity, multiple signaling molecules and a simplified depiction of their
interactions are diagrammed. While these signaling pathways are active in multiple cell
types, the diagram and the supporting data are limited to the endothelial cell, as endothelial
cells are thought to be the primary target of these agents in the treatment of cancer. Many
more interactions and molecules have been described as important to angiogenesis and to
VEGF signaling. This diagram, however, limits its scope to the molecules inhibited by the
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depicted agents and the immediately interacting signaling molecules shown primarily in
mammals or mammalian cell lines.
A clickable version of the VEGF pathway diagram and an Excel spreadsheet containing
references for the pathway interactions depicted in Fig. 1 may be accessed at the
Pharmacogenomics Knowledge Base (PharmGKB) at
http://www.pharmgkb.org/do/serve?objId=PA2032&objCls=Pathway.
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Representation of genes of the vascular endothelial growth factor (VEGF) signaling pathway
and the sites at which bevacizumab, sorafenib, sunitinib, brivanib, and cilengitide are known
to act.
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